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In computing the probability that a woman is a BRCA1 or BRCA2 carrier for genetic counselling purposes, it is important to
allow for the fact that other breast cancer susceptibility genes may exist. We used data from both a population based series of
breast cancer cases and high risk families in the UK, with information on BRCA1 and BRCA2 mutation status, to investigate
the genetic models that can best explain familial breast cancer outside BRCA1 and BRCA2 families. We also evaluated the
evidence for risk modiﬁers in BRCA1 and BRCA2 carriers. We estimated the simultaneous effects of BRCA1, BRCA2, a third
hypothetical gene ‘BRCA3’, and a polygenic effect using segregation analysis. The hypergeometric polygenic model was used to
approximate polygenic inheritance and the effect of risk modiﬁers. BRCA1 and BRCA2 could not explain all the observed
familial clustering. The best ﬁtting model for the residual familial breast cancer was the polygenic, although a model with a
single recessive allele produced a similar ﬁt. There was also signiﬁcant evidence for a modifying effect of other genes on the
risks of breast cancer in BRCA1 and BRCA2 mutation carriers. Under this model, the frequency of BRCA1 was estimated to
be 0.051% (95% CI: 0.021–0.125%) and of BRCA2 0.068% (95% CI: 0.033–0.141%). The breast cancer risk by age 70 years,
based on the average incidence over all modiﬁers was estimated to be 35.3% for BRCA1 and 50.3% for BRCA2. The
corresponding ovarian cancer risks were 25.9% for BRCA1 and 9.1% for BRCA2. The ﬁndings suggest that several common,
low penetrance genes with multiplicative effects on risk may account for the residual non-BRCA1/2 familial aggregation of
breast cancer. The modifying effect may explain the previously reported differences between population based estimates for
BRCA1/2 penetrance and estimates based on high-risk families.
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Of the breast cancer susceptibility genes which have been identi-
ﬁed to date, BRCA1 and BRCA2 are the most important ‘high
risk’ genes accounting for the majority of families with multiple
cases of breast and ovarian cancer. Other breast cancer suscept-
ibility alleles include mutations in the TP53 gene (Malkin et al,
1990), mutations in the PTEN gene (Nelen et al, 1996) and rare
HRAS1 mutations (Krontiris et al, 1993). There is also evidence
that heterozygous carriers of the ATM gene are at increased risks
of breast cancer (Easton, 1994; Swift et al, 1991; Olsen et al,
2001). But even if the effects of all the identiﬁed genes are taken
together, it is estimated that they can explain only 20–25% of
the familial relative risk for breast cancer (Easton, 1999; Rebbeck,
1999). Evidently other breast cancer susceptibility genes may
exist. However, it is unclear whether the residual familial aggre-
gation is due to rare mutations conferring a high risk of the
disease, similar to BRCA1/2, or to common but lower risk
variants.
In genetic counselling it is important to have an accurate
genetic model on which to base estimates of mutation carrier
probabilities and cancer risks. Such a model needs to incorpo-
rate both the effects of both the known susceptibility genes
(BRCA1 and BRCA2) and of other possible breast cancer
susceptibility genes. The existing genetic models are either based
on a single susceptibility gene (Claus et al, 1991) or take into
account only the effects of BRCA1 and BRCA2 (Parmigiani et
al, 1998) and hence they do not describe the familial breast
cancer adequately.
In this study we have combined data from a population-
based series of breast cancer cases with data from high risk
families, to investigate the genetic models that can explain
familial breast cancer outside BRCA1 and BRCA2 families,
and evaluate the evidence for risk modiﬁers in BRCA1 and
BRCA2 mutation carriers. In a previous analysis of the popula-
tion based Anglian Breast Cancer study (Antoniou et al, 2001),
we have demonstrated that the familial aggregation of breast
cancer can be adequately explained by the effects of BRCA1,
BRCA2 and a polygenic component (i.e. a large number of
low risk polymorphisms acting multiplicatively). Here we inves-
tigate how these models ﬁt data on high risk families, and
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carriers.
MATERIALS AND METHODS
Anglian Breast Cancer (ABC) study
The data collection for this study is described in more detail else-
where (The Anglian Breast Cancer Study Group 2000; Antoniou et
al, 2001). One thousand four hundred and eighty four cases diag-
nosed with breast cancer under the age 55 years were identiﬁed in
the region served by the Anglian Cancer Registry between 1991 and
1996. The cases were invited to provide blood sample and to
complete an epidemiological questionnaire including information
on family history of cancer in all ﬁrst degree relatives. Genomic
DNA, extracted from the blood, was screened for BRCA1 and
BRCA2 mutations by Conformation Sensitive Gel Electrophoresis
(CSGE), and mutations were conﬁrmed by sequencing.
Multiple case families
One hundred and ﬁfty six families were ascertained in response to
national publicity in the UK and by referral by oncologists or
general practitioners. Each family contained two or more breast
cancer cases, at least one of which was diagnosed under age 50
years. Cancer occurrence and follow up was recorded on all family
members. At least one individual from each family had DNA
samples analyzed for BRCA1 and BRCA2 mutations by CSGE.
These families are referred to as the ‘B’ families.
Statistical methods
The analysis was based on breast and ovarian cancer occurrence in
the combined dataset of the ‘B’ families and the ABC study. All indi-
viduals were censored at age 80 years, the age of their ﬁrst cancer or
their age of death, whichever occurred ﬁrst. Thus, only information
on the ﬁrst cancer was included in the analysis. Individuals known
to have died but with unknown age at death were censored at age
last at follow up or at age 70 years, whichever was smaller. If it
was known that an individual had developed breast or ovarian
cancer, but the age at diagnosis was unknown, we treated the age
at interview or age at death, whichever was smaller, as the age of
cancer. Individuals with no age information were treated as lost at
follow up and were censored at age zero years. Females who had
had prophylactic oophorectomy were censored for both breast and
ovarian cancer at the age of the surgery since oophorectomy is
known to reduce the risk of breast cancer as well as ovarian cancer.
Females who had had mastectomy were censored for breast cancer at
the age of the surgery. The analyses were implemented using the
computer program MENDEL (Lange and Weeks, 1988) which we
parallelized to run on a Hitachi SR2201 parallel computer of the
University of Cambridge High Performance Computing Facility.
Models
We modelled the simultaneous effects of BRCA1, BRCA2, a third
hypothetical gene BRCA3 which was assumed to have increased
risks of breast cancer, and a polygenic effect. The models for this
analysis are described in detail elsewhere (Antoniou et al, 2001).
Brieﬂy, the breast cancer incidence rate l(t) was assumed to be
based on the Cox model (Cox and Oakes, 1984),
l(t)=l0(t)exp(G+P). l0(t) is the baseline incidence rate, G depends
on the major genotype and P is the polygenic component, which is
assumed to be normally distributed with zero mean and variance
2
p. The polygenic component P was assumed to act in BRCA1
and BRCA2 carriers as well as non-carriers. However, we also ﬁtted
models in which P had no effect in BRCA1/2 carriers, and models
in which the variance of the polygenic ‘modifying’ component was
allowed to take a different value 2
m. The Hypergeometric Polygenic
Model (HPM) (Lange, 1997a,b) was used to approximate the poly-
genic and modifying components, where P was approximated by
P 
R ÿ N

N
2
r
p
:
R has a binomial distribution (2N, 1
2) according to the HPM and N
is the number of loci used in the HPM, which was set equal to 3 in
our analyses.
The ovarian cancer incidence rates were based on a similar
model, but we assumed that the polygenotype and the modifying
genes did not have any effect on the ovarian cancer risks. BRCA3
carriers were assumed to develop ovarian cancer according to the
general population incidence rates. Breast and ovarian cancers were
assumed to occur independently conditional on genotype.
The overall breast and ovarian cancer incidence rates were
constrained to agree with the national incidence rates for England
and Wales (1983–1987). The implementation of these constraints
is described elsewhere (Antoniou et al, 2001). In order to estimate
the BRCA1 and BRCA2 cancer risks, we assumed that the observed
incidence rates for BRCA1 and BRCA2 mutation carriers were a
constant multiple (RR) of the Breast Cancer Linkage Consortium
(BCLC) rates (Easton et al, 1993; Ford et al, 1998). We then inves-
tigated the effect of allowing the relative risks (RR) to vary with
age. For the models allowing for the modifying effect of other
genes on the breast cancer risks of BRCA1 and BRCA2, we
assumed that the observed incidence rate was the average over all
possible modifying effects.
In the ABC families, only the index case was tested for BRCA1
and BRCA2 mutations. In the ‘B’ families, mutation testing was
ﬁrst performed on an index affected individual. If a mutation
was found, other relatives were then screened for the same muta-
tion. For the index cases we assumed that the sensitivity of the
mutation testing was 64%, previously estimated by the Breast
Cancer Linkage Consortium for similar methodologies (Ford et
al, 1998). For any other relatives the mutation screening was
assumed to be 100% sensitive and 100% speciﬁc. In the ABC study
only the index patient was tested, and the screening sensitivity was
assumed to be 64%.
Estimation
The genetic models were speciﬁed in terms of the breast and ovar-
ian cancer incidence rates in BRCA1/2 carriers, the allele
frequencies, the number of loci (N) in the HPM and the standard
deviation for the polygenic and modifying components, sp and sm.
Maximum likelihood estimation was used to estimate the para-
meters. For the ABC families we maximized the conditional
likelihood of observing the disease phenotypes and mutation status
given the disease phenotype of the index case. For the ‘B’ families,
which were ascertained on the basis of multiple affected indivi-
duals, we conditioned on the disease phenotypes of all family
members.
The variances of the parameters were estimated by inverting the
observed information matrix. To compute conﬁdence intervals we
used transformed values of the parameters which provide estimates
which are normally distributed. Gene frequencies were transformed
using the logit function log p1ÿ p, while for relative risks and
2
p and 2
m we used the log transformation.
Goodness of ﬁt
The goodness of ﬁt of the models was tested using likelihood based
tests. Starting from a ‘sporadic’ model (i.e. only the BRCA1 and
BRCA2 effects taken into account), we tested if the addition of
parameters improved the ﬁt signiﬁcantly. The models were
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wise fashion. Non-nested models were compared using the
Akaike Information Criterion (Akaike, 1974):
AIC ÿ 2ln lik  2no: of independent parameters:
The model that minimizes AIC was chosen (Elston, 1990). For the
best ﬁtting models we also compared the predicted number of
mutations in index cases with the number observed.
Carrier probabilities
To calculate the number of mutations predicted by each model we
ﬁrst computed the probability that the index case was a mutation
carrier, on the basis of family history (FH) of breast or ovarian
cancer. Thus, the probability pj1 that the index case in family j
was a BRCA1 carrier was given by:
j1  PBRCA1jFHj
PBRCA1;FHj
PFHj
1

PBRCA1;FHj
PBRCA1;FHjPBRCA2;FHjPNon ÿ BRCA1=2;FHj
2
These probabilities were computed in MENDEL as the ratio of the
likelihood of observing the family with the BRCA1 mutation
divided by the likelihood of observing all possibilities. The total
number of BRCA1 mutations was then obtained by summing pj1
over all families. BRCA2 predictions were computed similarly.
RESULTS
ABC families
Table 1 summarizes the pedigrees by the number of breast and
ovarian cancer cases diagnosed under age 80 years. One thousand
two hundred and eighty probands did not have any family history
of breast or ovarian cancer in the ﬁrst degree relatives. One
hundred and sixty-nine cases had one ﬁrst degree relative diag-
nosed with breast cancer and 11 had two ﬁrst degree relatives
diagnosed with breast cancer. Twenty-three cases had one relative
that developed ovarian cancer under age 80 years, and one case
had one breast cancer case and one ovarian cancer case in ﬁrst
degree relatives. There were some differences between the present
analysis and the previous analysis of the ABC dataset (Antoniou
et al, 2001), with regard to the number of mutations. Three muta-
tions previously thought to be disease causing have been
reclassiﬁed as non-disease causing, while ﬁve new mutations have
been found by reevaluating the CSGE gels. In total there were eight
BRCA1 mutations and 15 BRCA2 mutations. Six of the BRCA1
mutation carriers did not have any family history of breast or ovar-
ian cancer in ﬁrst degree relatives and two had a relative diagnosed
with breast cancer under age 80 years. Nine BRCA2 mutation
carriers had no family history of breast or ovarian cancer, ﬁve
had one relative that developed breast cancer and one had two ﬁrst
degree relatives diagnosed with breast cancer. Mutations were not
identiﬁed in any of the 24 index cases with a family history of
ovarian cancer.
‘B’ families
Table 2 shows the families grouped by the number of breast cancer
cases diagnosed under age 50 years and the number of ovarian
cancer cases diagnosed under age 80 years. Eighteen families had
at least three breast cancer cases diagnosed under age 50 years
and at least one ovarian cancer case. Twenty families had at least
four breast cancer cases diagnosed under age 50 years and no ovar-
ian cancer cases. Twenty ﬁve families had only three breast cancer
cases diagnosed under age 50 years, three families had two breast
cancer cases and at least one ovarian cancer case, 66 families had
two breast cancer cases under age 50 years and 24 families had
one breast cancer case diagnosed under age 50 years. In total there
were 618 cases of breast cancer diagnosed at any age and 32 cases
of ovarian cancer. 21 (13%) of the index cases were tested positive
for BRCA1 mutations and 18 (11.5%) tested positive for BRCA2
mutations. The majority of the mutations were in families with
at least three breast cancer cases. In total, 318 individuals were
tested for BRCA1 and BRCA2 mutations (including the index
cases). Fifty seven BRCA1 mutation carriers and 74 BRCA2 muta-
tion carriers were identiﬁed.
Segregation analysis
Major gene models Table 3 summarizes the results for the major
gene models for BRCA3 incorporating BRCA1 and BRCA2 muta-
tions into the models but no allowance for polygenic effects. In
these, we assumed that BRCA3 mutations conferred a constant
relative risk over all age groups relative to the background inci-
dence rates. The major gene models included a dominant, a
recessive and a general model where the homozygous and hetero-
zygous carriers were assumed to have different relative risks. All
three models ﬁtted signiﬁcantly better than the sporadic model
(P50.0001). The general model converged to the recessive model
which had the lowest AIC among these models. Under the recessive
model, BRCA3 was estimated to have an allele frequency of 33%
with a cumulative breast cancer risk of 27.6% by age 70 years in
the homozygous carriers. The mutation frequencies were estimated
to be 0.042% for BRCA1 and 0.054% for BRCA2. The breast
cancer risk by age 70 years was estimated to be 49.6% for BRCA1
and 82.2% for BRCA2. The corresponding ovarian cancer risks
were 32.8% for BRCA1 and 17.8% for BRCA2.
Polygenic models The results for the polygenic models are
shown in Table 4. The inclusion of the polygenic component
(2
p) improved the ﬁt signiﬁcantly over the sporadic model
(P50.0001). There was also signiﬁcant evidence for a modifying
effect on the breast cancer risks of BRCA1 and BRCA2 mutation
carriers (2
p, 2
m, P=0.0238). But there was no evidence for a differ-
ence between the ‘modifying variance’ 2
m and the polygenic
variance in non carriers. Thus the model with a single polygenic
variance term was the most parsimonious. We also tested a model
with different modifying variances in BRCA1 and BRCA2 carriers.
Under this model, the BRCA1 modifying variance reached an arti-
ﬁcial upper boundary of 2.0, but the BRCA2 modifying variance
converged to a lower value (1.423). This was due to the absence
of family history of breast cancer in BRCA1 mutation carriers in
the ABC families. However, the model was not a signiﬁcantly better
ﬁt over the model with a common variance in BRCA1 and BRCA2
carriers.
E
p
i
d
e
m
i
o
l
o
g
y
Table 1 ABC pedigrees by number of female ﬁrst cancers under age 80
years and number of mutations
Number of mutations
Number of cases Number of pedigrees BRCA1 BRCA2
1 BrCa 1280 6 9
2 BrCa 169 2 5
3B r C a 1 1 – 1
1 BrCa, 1 OvCa 23 – –
2 BrCa, 1 OvCa 1 – –
Total 1484 8 15
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(2
p  2
m) the allele frequency for BRCA1 mutations in the general
population was estimated to be 0.056% (95% CI: 0.023–0.132%)
and the allele frequency for BRCA2 mutations was 0.072% (95%
CI: 0.037–0.143%). The standard deviation for the polygenic and
modifying effects was estimated to be 1.291 (95% CI: 1.096–
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Table 2 Observed (OBS) and expected number of mutations for the ‘B’ and ABC Families. The ‘B’ families are ca-
tegorized according to the number of breast cancer cases diagnosed under age 50 years, and the number of ovarian
cancer cases. The ABC families are categorized according to family history (FH) of breast or ovarian cancer. All the
predictions are under the recessive (REC) and polygenic (POL) models (2
p  2
m) of Tables 3 and 4
‘B’ families ABC families
Mutation Fam type OBS REC POL Fam type OBS REC POL
BRCA1 53 brca 9 6.05 5.86 6 6.57 6.43
BRCA2 51 ovca 3 3.13 3.05 7ve FH 9 8.48 8.24
No mutation 6 8.82 9.09 1265 1264.95 1265.34
BRCA1 54 brca 5 3.45 3.64 2 5.01 4.83
BRCA2 0 ovca 6 4.58 4.75 +ve FH 6 7.37 7.27
No mutation 9 11.98 11.61 196 191.62 191.90
BRCA1 3 brca 3 2.42 2.70
BRCA2 0 ovca 3 3.15 3.46
No mutation 19 19.42 18.85
BRCA1 2 brca 1 0.86 0.82
BRCA2 51 ovca 0 0.09 0.12
No mutation 2 2.05 2.06
BRCA1 2 brca 1 1.69 1.87
BRCA2 0 ovca 4 4.31 4.52
No mutation 61 60.01 59.61
BRCA1 1 brca 2 0.37 0.41
BRCA2 Any ovca 2 1.16 1.21
No mutation 20 22.47 22.38
BRCA1 Totals 21 14.83 15.30 Totals 8 11.57 11.26
BRCA2 18 16.42 17.10 15 15.85 15.51
No mutation 117 124.75 123.60 1461 1456.57 1457.23
Table 3 Segregation analysis with MENDEL; major gene models
Parameters Sporadic Dominant Recessive General
p ˆ1 0.0005829 0.0004451 0.0004192 0.0004192
(0.026–0.132%) (1.5610
77–0.57) (0.015–0.11%) (0.015–0.11%)
p ˆ2 0.0006760 0.0005558 0.0005426 0.0005426
(0.033–0.14%) (8.4610
78–0.786) (0.021–0.14%) (0.021–0.14%)
p ˆ3 NA 0.1462 0.3316 0.3316
(1.27610
79–1.0) (11.2–66.2%) (11.2–66.2%)
R ˆR BRCA3:
Heterozygotes NA 15.77 NA 1.00
(0.00–inf)
Homozygotes NA 15.77 15.61 15.61
(14.99–16.25)
R ˆR BRCA1:
Breast 0.3200 0.4894 0.5532 0.5532
(0.19–0.56) (0.00–inf) (0.23–1.35) (0.23–1.35)
Ovarian 0.7562 0.7386 0.7439 0.7439
(0.24–2.40) (0.007–74.17) (0.23–2.36) (0.23–2.36)
R ˆR BRCA2:
Breast 0.5578 0.8430 0.9404 0.9404
(0.34–0.91) (0.0–inf) (0.39–2.25) (0.39–2.25)
Ovarian 0.6482 0.6339 0.6252 0.6252
(0.24–2.40) (0.007–74.17) (0.23–2.36) (0.23–2.36)
(0.14–2.42) (0.003–134.54) (0.18–2.19) (0.18–2.19)
Log-likelihood 71885.017 71856.748 71854.833 71854.833
Data contributions:
ABC families 71712.436 71683.309 71681.502 71681.502
‘B’ families 7172.581 7173.439 7173.331 7173.331
Degrees of freedom 6 8 8 9
AIC 3782.034 3729.496 3725.666 3727.666
p ˆ1, p ˆ2, p ˆ3: BRCA1, BRCA2 and BRCA3 allele frequencies. RR: The relative risks as compared to non-carriers for BRCA3 and relative to
the BCLC rates for BRCA1 and BRCA2 carriers (Easton et al., 1993; Ford et al., 1998). 95% Conﬁdence intervals in parentheses.
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and BRCA2 carriers, relative to the BCLC risks (Easton et al,
1993; Ford et al, 1998) were all estimated to be less than one.
The cumulative breast cancer risk for a BRCA1 mutation carrier,
based on the observed incidence, was estimated to be 36.5% by
age 70 years and the ovarian cancer risk 28.5%. The cumulative
breast cancer risk for a BRCA2 mutation carrier was estimated to
be 68.7% and the corresponding ovarian cancer risk was 16.6%.
To estimate more precisely the shape of the incidence curves for
BRCA1 and BRCA2 mutation carriers, we ﬁtted a model where
separate breast cancer relative risks were assumed for ages 20–
39, 40–49, 50–59 and 60–79 years, for both BRCA1 and BRCA2
mutation carriers. We also allowed for separate ovarian cancer rela-
tive risks in the age groups 30–49, 50–59, and 60–69 years for
BRCA1 and in the age groups 30–49 and 50–69 years for BRCA2.
The number of ovarian cancer cases were not sufﬁcient to allow the
age speciﬁc ovarian cancer risks to be estimated in any more detail.
Where the relative risks applied to two decades of age, we assumed
that the ratio of incidence rates in those decades was the same as
the ratio from the analysis of the Breast Cancer Linkage Consor-
tium (Easton et al, 1995; Ford et al, 1998). The log-likelihood in
this case was maximized over 16 parameters and the estimates
are shown in Table 5 together with the age speciﬁc incidence rates
and cumulative risks. The model ﬁts signiﬁcantly better than the
model with constant relative risk (P=0.03). The BRCA1 and
BRCA2 mutation frequencies were estimated to be 0.051% (95%
CI: 0.021–0.125%) and the BRCA2 mutation frequency was
0.068% (95% CI: 0.033–0.141%) respectively. The standard devia-
tion for the polygenic and modifying effects was estimated to be
1.291 (95% CI: 1.097–1.519), identical to the model with constant
relative risks. The estimated breast cancer incidence rates for
BRCA1 increase up to the age group 40–49 years but then
decrease, while the incidence rates for BRCA2 mutation carriers
increase with age. The relative risk of breast cancer as compared
with the population incidence rates decrease sharply with age for
BRCA1 mutation carriers, from 23.88 in the 30–39 year age group
to 2.31 in the age group 60–69 years (Ptrend=0.005). In contrast,
the estimated breast cancer relative risk for BRCA2 mutation
carriers as compared to population incidence was 17.52 for the
age group 30–39 years but virtually constant over age 40 years
at around 11–12 (Ptrend=0.697). The ovarian cancer incidence rates
in BRCA1 carriers rise to a peak in the 40–49 years age group,
followed by a slight decline, while the BRCA2 ovarian cancer inci-
dence rates were highest in the 50–59 year age group.
The average risk of breast cancer for non-carriers, over all poly-
genic effects, is estimated to be 4.89% by age 70 years. Based on the
10 and 90% percentiles of the distribution of the polygenic compo-
nent the cumulative breast cancer risks are 0.3 and 17.9%
respectively. The cumulative breast cancer risk in BRCA1 mutation
carriers over all modiﬁers is estimated to be 35.26% by age 70
years. This is lower than the estimate based on the Breast Cancer
Linkage Consortium data of 71% (Easton et al, 1993). The esti-
mated breast cancer risks at the 10 and 90% percentiles of the
distribution of the modifying effect are 3.7 and 92.1% respectively.
The average breast cancer cumulative risk by age 70 years in
BRCA2 mutation carriers is 50.26% (7.2 and 99.3% at the 10
and 90% percentiles respectively). This is also lower than the BCLC
estimate of 84% (Ford et al, 1998).
Predicted number of mutations
The predicted number of mutations under the best ﬁtting major
gene and polygenic model (with a single relative risk parameter
over all age groups) are shown in Table 2. The predicted numbers
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Table 4 Segregation analysis with MENDEL. Polygenic models
Parameters included in the model
Parameters Sporadic 2
p 2
p; 2
m a 2
p  2
m 2
p; 2
m1; 2
m2
p ˆ1 0.0005829 0.0004208 0.0006387 0.0005567 0.0006639
(0.026–0.132%) (0.020–0.090%) (0.027–0.15%) (0.02–0.13%) (0.03–0.16%)
p ˆ2 0.0006760 0.0005401 0.0007950 0.0007240 0.0007491
(0.033–0.14%) (0.030–0.097%) (0.04–0.16%) (0.04–0.14%) (0.04–0.16%)
R ˆR BRCA1:
Breast 0.3200 0.5357 0.3104 0.3664 0.2930
(0.19–0.56) (0.335–0.882) (0.163–0.591) (0.197–0.681) (0.147–0.586)
Ovarian 0.7562 0.7457 0.6065 0.6274 0.5843
(0.24–2.40) (0.246–2.262) (0.212–1.734) (0.216–1.823) (0.202–1.693)
R ˆR BRCA2:
Breast 0.5578 0.913 0.5532 0.6335 0.6076
(0.34–0.91) (0.616–1.354) (0.324–0.945) (0.386–1.039) (0.316–1.168)
Ovarian 0.6482 0.6305 0.5746 0.5801 0.5537
(0.14–2.42) (0.196–2.024) (0.187–1.764) (0.186–1.806) (0.176–1.745)
^  p NA 1.269 1.286 1.291 1.280
(1.076–1.497) (1.091–1.516) (1.096–1.521) (1.085–1.511)
^  m NA NA 2.00 1.291 NA
NA (1.096–1.521)
^  m1 NA NA NA NA 2.00
^  m2 NA NA NA NA 1.423
(0.481–4.212)
Log-likelihood 71885.017 71856.371 71853.818 71854.340 71853.675
Data contributions:
ABC families 71712.436 71683.059 71681.398 71682.035 71681.508
‘B’ families 7172.581 7173.312 7172.420 7172.305 7172.167
Degrees of freedom 6 7 8 7 9
AIC 3782.034 3726.742 3723.636 3722.680 3725.350
a04sm42.0. p1, p2: BRCA1 and BRCA2 allele frequencies. RR: The relative risks as compared to the BCLC rates (Easton
et al., 1995; Ford et al., 1998). 95% Conﬁdence intervals in parentheses.
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mutations for the ABC families were similar to the observed
number for index cases without family history of breast or ovarian
cancer but they were slightly higher than observed for the index
cases with positive family history of the diseases. For the ‘B’
families, the predicted number of BRCA2 mutations is very similar
to the observed number, but the number of BRCA1 mutations is
somewhat higher than predicted (21 vs 15.30 respectively for the
polygenic model). The predicted number of mutations did not
change much when separate relative risk parameters were assumed
over all age groups for the polygenic model. In the ABC families,
10.44 BRCA1 mutations and 15.67 BRCA2 mutations were
predicted (compared to eight and 15 observed respectively), while
in the ‘B’ families 15.96 BRCA1 mutations and 16.72 BRCA2 muta-
tions were predicted (compared to 21 and 18 observed
respectively).
DISCUSSION
We investigated the genetic models for familial breast cancer in a
combined dataset consisting of both high-risk families and a popu-
lation based series of breast cancer cases. We found the most
parsimonious model to be one with a polygenic component with
an equal variance in BRCA1/2 carriers and in non-carriers. This
corresponds to a model in which several polymorphisms each act
multiplicatively on risk (by for example, increasing the rate at
which key mutational events will occur) to the same extent on
carriers and non-carriers. A common recessive allele with moderate
penetrance had the best ﬁt among the major gene models ﬁtted for
‘BRCA3’. However, the evidence for a major gene is weakened by
the fact that the contribution of the ‘B’ families to the overall log-
likelihood is always smaller under the major gene models for
BRCA3 than their contribution under the sporadic model. On
the other hand, the contribution of the ‘B’ families is larger under
the polygenic models (with modiﬁers) than under the sporadic
model.
Under the best ﬁtting model (2
p  2
m), the frequency of
BRCA1 mutations in the general population was estimated to
be 0.051% (95% CI: 0.021–0.125%) which corresponds to about
one in 974 individuals being a BRCA1 carrier. This is very simi-
lar to the estimate of Ford et al. (1995) of one in 800. Higher
estimates were obtained by Whittemore et al. (1997) (0.14%)
and Antoniou et al. (2000) (0.13%). These studies were,
however, based on segregation analysis of ovarian cancer and
may be inﬂated by not allowing for other familial effects. The
estimate from the ABC dataset alone was 0.023% (Antoniou et
al, 2001), lower than the estimate from our combined analysis
but included in the conﬁdence interval. The mutation frequency
for BRCA2 mutations was estimated to be 0.068% (95% CI:
0.033–0.141%). This corresponds to one in 734 individuals
being a BRCA2 carrier in the general population. Again this is
somewhat lower than 0.17% estimated in the ovarian cancer
segregation analysis of Antoniou et al. (2000) (0.17%). The
frequency from the ABC analysis alone was again somewhat
lower, 0.041% (Antoniou et al, 2001).
The fact that the observed number of BRCA1 mutations in the
‘B’ families was higher than predicted might suggest that we have
slightly underestimated the BRCA1 allele frequency as a conse-
quence of ﬁnding (by chance) too few BRCA1 mutations in the
ABC study. Alternatively it may be that the sensitivity of mutation
testing was lower in the much larger ABC study, although it is not
clear why this should be true only for BRCA1.
Under our best ﬁtting model the breast cancer risk for BRCA1
carriers, based on the average incidence over all modifying effects,
was estimated to be 35.3% by age 70 years. This is moderately
lower than the estimates derived by the BCLC studies of high risk
families, which are in the range 71–85% (Easton et al, 1993, 1995)
and also slightly lower than the estimates derived from risks to
relatives of mutation carriers in population based series of breast
cancer patients (Struewing et al, 1997; Hopper et al, 1999). These
differences are broadly consistent with our best model, since cases
in high risk families will be expected to have a much larger poly-
genic component than average, while relatives of early onset breast
cancer cases will be expected to have only a slightly higher poly-
genic component than average. The ovarian cancer risk for
BRCA1 mutation carriers is estimated to be 26% by age 70 years.
This is somewhat higher than the estimate of Struewing et al.
(1997) but lower than the BCLC estimates (50.6–63.3%) (Easton
et al, 1993, 1995). It is also lower than our previous estimate based
on ovarian cancer families (66%) (Antoniou et al, 2000). The high-
er estimates from the last two studies are based on families that
were selected on the basis of either ovarian cancer cases or number
of breast and ovarian cancer cases, and could be the result of
modifying genes or other familial factors increasing ovarian cancer
risks. In principle, our model could be extended to account for
such modifying factors.
The cumulative risk of breast cancer for BRCA2 mutation
carriers was estimated to be 50.3% by age 70 years. Again this is
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Table 5 Parameters for the polygenic model with 2
p  2
m and different breast and
ovarian cancer relative risks over age groups
BRCA1 BRCA2
Non-carriers
Incidence Risk RR
a Incidence Risk RR
a risk
Breast cancer
30–39 0.011222 0.1286 23.88 0.008236 0.0831 17.52 0.0036
40–49 0.016621 0.2620 12.40 0.014471 0.2067 10.80 0.0146
50–59 0.008255 0.3205 4.91 0.020352 0.3527 12.11 0.0298
60–69 0.004843 0.3526 2.31 0.026326 0.5026 12.53 0.0489
Ovarian cancer
30–39 0.000206 0.0041 3.43 0.000220 0.0032 3.67 0.0007
40–49 0.011730 0.1143 53.32 0.000440 0.0076 2.00 0.0023
50–59 0.008134 0.1835 20.86 0.004622 0.0524 11.85 0.0058
60–69 0.009756 0.2594 19.51 0.004161 0.0910 8.32 0.0104
Frequency 0.00051 0.0068
2
p; 2
m 1.291
Log-likelihood 71844.975
Contributions; ABC: 71679.324, ‘B’: 7165.561
AIC: 3721.950
aRelative risk as compared to population incidence rates.
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to the estimates of the population based study of Hopper et al.
(1999). The corresponding ovarian cancer risk by age 70 years
was estimated to be 9.1%. This is lower than the ﬁrst BCLC esti-
mate (27%) (Ford et al, 1998) and the estimate based on ovarian
cancer families (31%) (Antoniou et al, 2000). It is also somewhat
lower than the estimate from a recent BCLC study of genotype-
phenotype correlations (14%) (Thompson and Easton, 2001) and
the estimate of Struewing et al. (1997) based on carriers of Ashke-
nazi Jewish founder mutations.
We found that the breast cancer incidence rates in BRCA1
mutation carriers relative to the population incidence rates
decrease sharply with age. This contrasts with the pattern in
BRCA2 carriers, in whom the relative risk is approximately
constant over age 40 years. Thus, BRCA2 mutations are estimated
to confer a breast cancer risk which is similar to the population
risk but 10–12 times greater. This difference in the pattern of inci-
dence rates is mirrored in the very different histopathology of
tumours in BRCA1 and BRCA2 carriers (Lakhani et al, 1998),
and reﬂects important mechanistic differences. A practical implica-
tion of these different age-incidence patterns, is that BRCA1
mutation carriers are more likely to develop breast cancer at a
younger age than BRCA2 mutation carriers.
The polygenic model suggests that several genes, each having
small but multiplicative effects on risk can account for the residual
non-BRCA1/2 familial clustering of breast cancer. Genes other than
BRCA1 and BRCA2 implicated in the aetiology of hereditary breast
cancer include the TP53 gene (Malkin et al, 1990), and the PTEN
gene (Nelen et al, 1996). Mutations in these genes, however,
predispose to rare autosomal dominant syndromes and their
contribution to familial aggregation is very small. Heterozygous
carriers of the ataxia-talangiectasia gene ATM have been reported
to be at increased risks of breast cancer (Swift et al, 1991; Easton,
1994; Olsen et al, 2001) and there is also evidence that rare HRAS1
alleles may be associated with moderate risks for breast cancer
(Krontiris et al, 1993). It has been suggested that genes involved
in steroid hormone metabolism and transport could act together
deﬁning a high-risk proﬁle for breast cancer (Henderson and
Feigelson, 2000). Genes included in this pathway include the
HSD17B1 gene, the CYP17 and CYP19 genes and the Estrogen
Receptor (ER) gene (Henderson and Feigelson, 2000). At present,
however, there is no clear evidence that polymorphisms in these
genes are associated with a signiﬁcant risk (Dunning et al, 1998).
In a meta-analysis of all the studies of low risk polymorphisms,
signiﬁcant evidence was found for carriers of the (TTTA)10
Cyp19 polymorphism, the GSTP1 Ile105Val polymorphism and
the TP53 Arg72Pro polymorphism (Dunning et al, 1998) but the
evidence was not conclusive.
Rebbeck et al. (1999b) found that BRCA1 carriers with long
repeat lengths of the (AG)n polymorphism at the Androgen Recep-
tor gene may have earlier age at diagnosis of breast cancer.
Similarly, the steroid hormone metabolism gene AIB1 has been
reported to modify the breast cancer risk in BRCA1 mutation
carriers (Rebbeck et al, 1999a). Carriers of a variant AIB1 allele
were found to have an age of diagnosis of breast cancer which is
on average 3 years younger than non-carriers. However, neither
of these results have been replicated.
The Hypergeometric Polygenic Model is equivalent to a fully
additive polygenic trait, with no dominance or epistatic variance
(Lange, 1997b). In practice some degree of dominance may exist,
given the slightly higher familial relative risks among sibs (Pharoah
et al, 1997). Among the major gene models ﬁtted, the recessive
model was the most parsimonious, and a recessive effect was also
found by Cui et al. (2001) in BRCA1/2 negative families. However,
some of the evidence for a recessive effect may be due to secular
increase in incidence, which would give rise to a higher risk to
siblings of probands, and to the protective effect of parity which
slightly reduces the risk to mothers of probands (Antoniou et al,
2001). It is also, of course, possible that some of the familial aggre-
gation modelled here in terms of genetic susceptibility may be due
to clustering of lifestyle risk factors (for example diet or reproduc-
tive factors) within families.
In conclusion, the present results suggest that a number of low
penetrant genes may account for the familial clustering of breast
cancer outside BRCA1 and BRCA2 families. The modifying effect
on the breast cancer risks of BRCA1 and BRCA2 carriers may
explain some of the differences between the risk estimates from
population based studies and high risk families. The resulting
model provides a framework for risk estimation to counsel women
with a family history of breast cancer, allowing one to estimate
carrier probabilities (separately for BRCA1 and BRCA2) and inci-
dence rates in the same analysis. The model can also be extended
straightforwardly to include risks of other cancers, second breast/
ovarian cancers and tumour pathology. In principle it should also
be possible to include lifestyle factors, although this would depend
on assumptions about their effects in susceptible individuals.
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